REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH

TYPE 2 DIABETES

1. **9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021**. *Diabetes Care*2021, **44**(Suppl 1):S111-s124.
2. Lipscombe L, Butalia S, Dasgupta K, Eurich DT, MacCallum L, Shah BR, Simpson S, Senior PA: **Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update**. *Can J Diabetes*2020, **44**(7):575-591.
3. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR*et al*: **CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY**. *Endocr Pract*2020, **26**(1):107-139.
4. Department of Veterans Affairs/Department of Defense: **VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus in Primary Care**. In*.*; 2017.
5. Diabetes\_Canada: **2018 Clinical Practice Guidelines Committees**. *Canadian Journal of Diabetes*2018, **42**.
6. American Diabetes Association: **Standards of Medical Care in Diabetes -2019**. *The Journal of Clinical and Applied Research and Education*2019, **42**.
7. Marso SP BS, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T: **Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.** *N Engl J Med*2016, **375**(19):1834-1844.
8. Husain M BA, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC: **Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.** *N Engl J Med*2019, **381**(9):841-851.
9. Holman RR BM, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group: **Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.** *N Engl J Med*2017, **377**(13):1228-1239.
10. Bruce Neal  VP, Kenneth W. Mahaffey,  Dick de Zeeuw,  Greg Fulcher,   Ngozi Erondu,  Wayne Shaw,   Gordon Law,  Mehul Desai, and David R. Matthews, for the CANVAS Program Collaborative Group: **Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes**. *The new england journal of medicine*2017, **377**(7).
11. Perkovic V JM, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW: **Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.** *N Engl J Med*2019, **380**(24).
12. **8. Pharmacologic Approaches to Glycemic Treatment**. *Diabetes Care*2017, **40**(Supplement 1):S64-S74.
13. Booth G, Lipscombe L, Butalia S, Dasgupta K, Eurich D, Goldenberg R, Khan N, MacCallum L, Shah B, Simpson S: **Pharmacologic management of type 2 diabetes: 2016 interim update**. *Canadian journal of diabetes*2016, **40**(6):484-486.
14. Association AD: **Standards of medical care in diabetes—2017 abridged for primary care providers**. *Clinical Diabetes*2017, **35**(1):5-26.
15. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA: **Consensus statement by the American association of clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2017 executive summary**. *Endocrine Practice*2017, **23**(2):207-238.
16. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ*et al*: **Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes**. *N Engl J Med*2015, **373**(22):2117-2128.
17. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS*et al*: **Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes**. *New England Journal of Medicine*2016, **375**(4):311-322.
18. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML: **Semaglutide and cardiovascular outcomes in patients with type 2 diabetes**. *New England Journal of Medicine*2016, **375**(19):1834-1844.
19. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR: **Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes**. *New England Journal of Medicine*2017.
20. AACE/ACE: **CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY**. *Endocrine Practice*2019, **25**.
21. Conditions NCCfC: **Type 2 diabetes: national clinical guideline for management in primary and secondary care (update)**. In*.* London: Royal College of Physicians; 2014.
22. CADTH: **New Drugs for Type 2 Diabetes: Second-Line Therapy - Recommendations Report**. *CADTH therapeutic review*2017 May, **4**(1c).
23. Hux J: **Subject: Diabetes Canada Feedback on New Drugs for Type 2 Diabetes: Second-Line Therapy: A Therapeutic Review Update**. 2017.
24. Arnason T, Mansell K: **Diabetes Mellitus**. In: *Therapeutics.* Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2017.
25. RxFiles: **Anti-hyperglycemic agents: comparison chart**

In: *RxFiles Drug Comparison Charts.* Edited by Regier L, Jensen B, Rutherford L. Saskatoon, SK: Saskatoon Health Region; 2017.

1. Canadian Diabetes Association Clinical Practice Guidelines Expert C, Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF: **Pharmacologic management of type 2 diabetes**. *Can J Diabetes*2013, **37 Suppl 1**:S61-68.
2. Dynamed: **Diabetes mellitus type 2 in adults**. In*.* Ipswich, MA: EBSCO Information Services; 2015.
3. NICE: **Type 2 diabetes in adults: management**. In: *NICE Guideline.* vol. NG28. London: National Institute for Health and Care Excellence; 2015.
4. NICE: **The management of type 2 diabetes**. In*.*, vol. CG87. London: National Institite for Health and Care Excellence; 2014.
5. SIGN: **Management of diabetes: a national clinical guideline**. In*.*, vol. 116. Edinburgh: Scottish Intercollegiate Guidelines Network; 2010.
6. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale J-F: **Pharmacologic Management of Type 2 Diabetes**. *Canadian Journal of Diabetes*2013, **37, Supplement 1**:S61-S68.
7. **Second- and Third-Line Pharmacotherapy for Type 2 Diabetes: Update**. Ottawa ON: Cadth 2013.; 2013.
8. Liu SC, Tu YK, Chien MN, Chien KL: **Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis**. *Diabetes, obesity & metabolism*2012, **14**(9):810-820.
9. Phung OJ, Scholle JM, Talwar M, Coleman CI: **Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes**. *Jama*2010, **303**(14):1410-1418.
10. Brunton S: **GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?** *International journal of clinical practice*2014, **68**(5):557-567.
11. Reid T: **Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence**. *Clinical Diabetes*2012, **30**(1):3-12.
12. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G: **Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial**. *Diabetes Care*2013, **36**(9):2508-2515.
13. Amate JM, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, Gonzalez-Canudas J: **Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis**. *International journal of clinical practice*2015, **69**(3):292-304.
14. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G: **Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial**. *Lancet (London, England)*2013, **382**(9896):941-950.
15. Dynamed: **Glycemic Goals in Type 2 Diabetes**. In*.* Ipswich, MA: EBSCO Information Services; 2015.
16. **PL Detail-Document, Stepwise Treatment of Type 2 Diabetes**. In*.*: Pharmacist's Letter/Prescriber's Letter; 2014.
17. Apotex Inc.: **Health Canada Endorsed Physician Communication**. In*.* Toronto, Ontario: Apotex Inc.; 2016.
18. Canadian Diabetes Association Clinical Practice Guidelines Expert C, Imran SA, Rabasa-Lhoret R, Ross S: **Appendix 6: Therapeutic Considerations for Renal Impairment**. *Can J Diabetes*2013, **37 Suppl 1**:S207.
19. Apotex: **Apo-Tolbutamide**. In: *Product Monograph.* Weston, ON; 2010.
20. **Sulfonylureas [CPhA monograph]**. In: *CPS.* Ottawa (ON): Canadian Pharmacists Association; 2015.
21. Detailing PA: **Glucose Lowering Medications for Type 2 Diabetes**. In*.* BC Provincial Academic Detailing Service; Oct 2015.
22. Limited TC: **Ratio-Metformin**. In: *CA Product Monograph.* Toronto, ON: Teva Canada Limited; 2019.
23. Canada BH: **Glumetza (Metformin Hydrochloride Extended-Release Tablets)**. In: *CA Product Monograph.* Laval, QC: Bausch Health Canada Inc; 2020.
24. Bristol-Myers\_Squibb\_USA: **GLUCOPHAGE\_(metformin)US**. In: *FDA Product Monograph.* Princeton, NJ: Bristol-Myers\_Squibb\_USA; 2018.
25. Pharmaceuticals S: **Metformin Hydrochloride**. In: *FDA Product Monograph.* Hauppauge, NY: ScieGen Pharmaceuticals; 2021.
26. Canadian Diabetes Association Clinical Practice Guideline Expert C: **Appendix 5: Approxiamte cost reference list for antihyperglycemic agents**. *Canadian journal of diabetes*2016, **40**(6).
27. Committee GaPA: **Diabetes Care**. In*.*: Government of BC; 2010.
28. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK: **Metformin in patients with type 2 diabetes and kidney disease: a systematic review**. *Jama*2014, **312**(24):2668-2675.
29. BMJ: **Type 2 Diabetes in adults**. In: *BMJ Best Practice.* BMJ; 2017.
30. Lipska KJ, Bailey CJ, Inzucchi SE: **Use of metformin in the setting of mild-to-moderate renal insufficiency**. *Diabetes care*2011, **34**(6):1431-1437.
31. **PL Detail-Document, Clinical Use of Metformin in Special Populations**. In*.*: Pharmacist's Letter/Prescriber's Letter; 2015.
32. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR: **Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis**. *Diabetes Care*2008, **31**(11):2086-2091.
33. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G*et al*: **A common 5'-UTR variant in MATE2-K is associated with poor response to metformin**. *Clinical pharmacology and therapeutics*2011, **90**(5):674-684.
34. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, McCarty CA*et al*: **The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin**. *Clinical pharmacology and therapeutics*2013, **93**(2):186-194.
35. Eli Lilly Canada Inc: **TRULICITY (dulaglutide injection)**. In: *CA monograph.* Toronto, ON; 2020.
36. Eli\_Lilly\_and\_Company\_US: **TRULICITY (dulaglutide injection)**. In: *FDA Product Monograph.* Indianapolis, IN: Eli\_Lilly\_and\_Company\_US; 2020.
37. AstraZeneca Canada Inc: **Byetta (Exenatide injection)**. In: *CA Product Monograph.* Mississauga, ON: AstraZeneca Canada Inc; 2019.
38. Canada A: **BYDUREON (Exenatide extended release injectable suspension)**. In: *CA Product Monograph.* Mississauga, ON: AstraZeneca\_Pharmaceuticals\_LP\_US; 2019.
39. LP AP: **BYETTA-(exenatide\_injection)**. In: *FDA Product Monograph.* Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
40. LP AP: **BYDUREON-(exenatide\_injection,suspension,extended\_release)**. In: *FDA Product Monograph.* Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
41. Guidelines B: **Diabetes Care**. In*.* BC: BC Guidelines; 2015.
42. **KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update**. *American journal of kidney diseases : the official journal of the National Kidney Foundation*2012, **60**(5):850-886.
43. Canada NN: **Saxenda (Liraglutide injection)**. In: *CA Product Monograph.* Mississauga, ON: Novo Nordisk Canada; 2021.
44. Canada NN: **Victoza (Liraglutide injection)**. In: *CA Product Monograph.* Mississauga, ON: Novo Nordisk Canada; 2020.
45. Nordisk N: **Saxenda (Liraglutide injection)**. In: *FDA Product Monograph.* Plainsboro, NJ: Novo Nordisk; 2020.
46. Novo\_Nordisk\_US: **VICTOZA-(liraglutide\_injection)US**. In: *FDA Product Monograph.* Wilmington, DE: Novo\_Nordisk\_US; 2018.
47. Canada S-A: **Adlyxine (Lixisenatide)**. In: *CA Product Monograph.* Laval, QC: Sanofi-Aventis Canada; 2020.
48. US S-A: **Adlyxine (Lixisenatide)**. In: *FDA Product Monograph.* Bridgewater, NJ: Sanofi-Aventis US; 2021.
49. Novo\_Nordisk\_Canada: **Rybelsus (Semaglutide tablets)**. In: *CA Product Monograph.* 2020.
50. Novo\_Nordisk\_Canada: **Ozempic (Semaglutide)**. In: *Health Canada Monograph.* 2018.
51. Nordisk N: **Rybelsus (Semaglutide tablets)**. In: *US Product Monograph.* 2020.
52. Novo\_Nordisk: **Ozempic (Semaglutide)**. In: *US Product Monograph.* 2021.
53. Novo\_Nordisk\_US: **Semaglutide**. In: *FDA Product Monograph.* Dec2017 edn; 2017.
54. Janssen\_Pharmaceuticals\_Inc\_CA: **Canagliflozin**. In: *CA Product Monograph.* 2020.
55. Janssen\_Pharmaceuticals\_Inc\_US: **Canagliflozin**. In: *US Product monograph.* 2020.
56. **Glucose Lowering Medications for Type 2 Diabetes**[<http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/pad_glucose_lowering_medications_booklet.pdf>]
57. **Invokana [product monograph]**. In: *CPS.* Ottawa (ON): Canadian Pharmacists Association; 2017.
58. Janssen\_Pharmaceuticals\_Inc\_US: **INVOKANA-(canagliflozin\_tablet,film\_coated)US**. In: *FDA Product Monograph.* Titusville, NJ: Janssen\_Pharmaceuticals\_Inc\_US; 2018.
59. Canadian Diabetes Association Clinical Practice Guidelines Expert C: **Appendix 6: Therapeutic Considerations for Renal Impairment**. *Can J Diabetes*2015.
60. Abe M, Kalantar-Zadeh K: **Haemodialysis-induced hypoglycaemia and glycaemic disarrays**. *Nature Reviews Nephrology*2015, **11**(5):302-313.
61. Canada A: **Forxiga (dapagliflozin)**. In: *CA Product Monograph.* 2020.
62. AstraZeneca: **Farxiga (dapagliflozin)**. In: *US Product monograph.* 2020.
63. Boehringer\_Ingelheim\_Pharmaceuticals IC: **Jardiance (Empagliflozin)**. In: *CA Product Monograph.* 2020.
64. Boehringer\_Ingelheim\_Pharmaceuticals IU: **Jardiance (Empagliflozin)**. In: *FDA Product Monograph.* Ridgefield, CT; 2020.
65. Provincial Academic Detailing: **Glucose Lowering Medications for Type 2 Diabetes**. In*.* BC Provincial Academic Detailing Service; 2015.
66. Boehringer\_Ingelheim\_Pharmaceuticals IU: **Empagliflozin**. In: *FDA Product Monograph.* 2018.
67. **Jardiance  [product monograph]**. In: *CPS.* Ottawa (ON): Canadian Pharmacists Association; 2017.
68. Boehringer\_Ingelheim\_Pharmaceuticals IU: **JARDIANCE-(empagliflozin\_tablet,film\_coated)US**. In: *FDA Product Monograph.* Ridgefield, CT: Boehringer\_Ingelheim\_Pharmaceuticals,Inc\_US; 2018.
69. Takeda Canada Inc: **Nesina (Alogliptin)**. In: *CA Product Monograph.* 2021.
70. America TP: **Nesina (Alogliptin)**. In: *US Product Monograph.* 2021.
71. Detailing PA: **Glucose Lowering Medications for Type 2 Diabetes**. In*.* BC Provincial Academic Detailing Service; 2015.
72. Canada BI: **Trajenta**. In: *CA Product Monograph.* Burlington, ON: Boehringer Ingelheim Canada; 2021.
73. Boehringer\_Ingelheim\_Pharmaceuticals IU: **TRADJENTA (linagliptin\_tablet)**. In: *FDA Product Monograph.* Ridgefield, CT: Boehringer\_Ingelheim\_Pharmaceuticals,\_Inc.US; 2020.
74. Apotex Inc: **Apo-Saxagliptin**. In: *CA Product Monograph.* Toronto, ON: Apotex Inc; 2020.
75. Health C: **Onglyza - Saxagliptin tablet**. In: *FDA Product Monograph.* Dublin, OH: Cardinal Health; 2021.
76. Merck Canada Inc: **Januvia (Sitagliptin)**. In: *CA Product Monograph.* Kirkland, QC: Merck Canada Inc; 2021.
77. Corp. MSD: **Januvia (Sitagliptin)**. In: *FDA Product Monograph.* Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2020.
78. Limited TC: **Act-Pioglitazone**. In: *CA Product Monograph.* Toronto, ON: Teva Canada Limited; 2020.
79. Takeda\_Pharmaceuticals\_America\_ Inc.: **ACTOS (pioglitazone\_tablet)**. In: *FDA Product Monograph.* Lexington, MA: Takeda\_Pharmaceuticals\_America\_ Inc.; 2021.
80. AA Pharma Inc: **Rosiglitazone**. In: *CA Product Monograph.* Vaughan, ON: AA Pharma Inc; 2019.
81. LLC G: **Avandia (Rosiglitazone)**. In: *FDA Product Monograph.* Research Triangle Park, NC: GlaxoSmithKline LLC; 2020.
82. Health S: **Gliclazide**. In: *CA Product Monograph.* Brampton, ON; 2020.
83. Canada S: **Diamicron MR**. In: *CA Product Monograph.* Laval, QC; 2018.
84. **Adult Drug Book**In*.*: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
85. Canada S: **Diamicron MR**. In: *Product Monograph.* Laval, QC; 2016.
86. Canada S: **Diamicron**. In: *Product Monograph.* Laval, QC; 2016.
87. Sandoz Canada Inc: **Sandoz Glimepiride**. In: *CA Product Monograph.* Boucherville, QC; 2021.
88. US SH: **Glimepiride**. In: *FDA Product Monograph.* Somerset, NJ: Solco Healthcare US; 2021.
89. LTEE PD: **Glyburide**. In: *CA Product Monograph.* Laval, QC: Pro Doc LTEE; 2019.
90. Heritage Pharmaceuticals Inc: **Glyburide**. In: *FDA Product Monograph.* East Brunswick, NJ: Heritage Pharmaceuticals Inc; 2021.
91. Pharmacia\_and\_Upjohn\_Co\_U.S.: **Glynase- (glyburide)US**. In: *FDA Product Monograph.* NY, NY: Pharmacia\_and\_Upjohn\_Co\_U.S.; 2018.
92. Limited TC: **ACT REPAGLINIDE**. In: *CA Product Monograph.* Toronto, ON; 2020.
93. Pharmaceutical B: **Repaglinide**. In: *FDA Product Monograph.* Berlin, CT; 2020.
94. Canada SP: **Acarbose**. In: *CA Product Monograph.* Oakville, ON: Strides Pharma Canada; 2019.
95. Pharmaceuticals H: **Acarbose**. In: *FDA Product Monograph.* East Brunswick, NJ; 2021.
96. Canada NN: **Tresiba - insulin degludec**. In: *CA Product Monograph.* Mississauga, ON: Novo Nordisk Canada; 2021.
97. Nordisk N: **Tresiba - insulin degludec**. In: *FDA Product Monograph.* Plainsboro, NJ: Novo Nordisk; 2019.
98. Terra Arnason KM: **Diabetes Mellitus**. In: *Compendium of Therapeutic Choices.* February 2019 edn. Ottawa, Ontario: Canadian Pharmacists Association 2019.
99. Canada NN: **Levemir (Insulin\_detemir)**. In: *CA Product Monograph.* Mississauga, Ontario Novo Nordisk Canada Inc; 2021.
100. Nordisk N: **Levemir (Insulin\_detemir)**. In: *FDA Product Monograph.* Princeton, New Jersey Novo Nordisk; 2021.
101. Canadian\_Agency\_for\_Drugs\_and\_Technologies\_in\_Health: **Guide to Starting and Adjusting Insulin for Type 2 Diabetes**. In: *CADTH Reports.* Ottawa, Ontario: Canadian\_Agency\_for\_Drugs\_and\_Technologies\_in\_Health; 2012.
102. Diabetes\_Canada: **Insulin Prescription Tool for Healthcare Providers**. In: *Health-Care Provider Tools.* Toronto, Ontario: Diabetes\_Canada; 2017.
103. US NN: **Levemir\_(Insulin\_detemir)\_US**. In: *FDA Product Monograph.* Princeton, New Jersey Novo Nordisk Canada Inc; 2019.
104. Canadian\_Pharmacists\_Association: **Dosage Adjustment in Renal Impairment**. In: *Therapeutics.* Ottawa, Ontario: Canadian\_Pharmacists\_Association; 2018.
105. National\_Institutes\_of\_Health(USA): **Insulin\_LiverTox**. In: *LiverTox.* Bethesda, MD: U.S. National Library of Medicine; 2018.
106. Eli Lilly Canada Inc: **Basaglar (Insulin Glargine)**. In: *CA Product Monograph.* Toronto, ON: Eli Lilly Canada; 2021.
107. Company ELa: **Basaglar**. In: *FDA Product Monograph.* Indianapolis, IN: Eli Lilly and Company; 2021.
108. ELI\_LILLY\_Canada: **Basaglar\_(Insulin\_glargine)\_CA**. In: *CDN Product Monograph.* Scarborough, Ontario: ELI\_LILLY\_Canada; 2016.
109. LILLY\_USA: **Basaglar\_(Insulin\_glargine)\_US**. In: *FDA Product Monograph.* Indianapolis, IN LILLY\_USA; 2018.
110. ELI\_LILLY\_Canada: **Humulin R, Humulin N, Humulin 30/70**. In: *CA Product Monograph.* Toronto, Ontario: ELI\_LILLY\_Canada; 2021.
111. Company ELa: **Humulin N**. In: *FDA Product Monograph.* Indianapolis, IN; 2020.
112. Novo\_Nordisk\_Canada: **Fiasp - Insulin aspart**In: *CA Product Monograph.* Mississauga, Ontario: Novo Nordisk Canada Inc. ; 2020.
113. Novo\_Nordisk: **Novolog - insulin aspart**. In: *US Product Monograph.* Plainsboro, NJ: Novo Nordisk; 2021.
114. Sanofi-Aventis\_Canada\_Inc.: **Apidra (insulin glulisine)**. In: *CA Product Monograph.* Laval, QC: sanofi-aventis Canada Inc. ; 2021.
115. U.S. S-A: **Apidra (insulin glulisine)**. In: *FDA Product Monograph.* Bridgewater, NJ: Sanofi-Aventis U.S.; 2020.
116. ELI\_LILLY\_Canada: **Humalog\_(Insulin\_lispro)\_CA**. In: *CDN Product Monograph.* Toronto, ON: ELI\_LILLY\_Canada; 2021.
117. Company ELa: **Humalog (insulin lispro)**. In: *FDA Product Monograph.* Indianopolis, IN: Eli Lilly and Company; 2021.
118. Company ELa: **Humulin R**. In: *FDA Product Monograph.* Indianapolis, IN: Eli Lilly and Company; 2020.
119. Corporation M: **Afrezza (insulin human powder)**. In: *FDA Product Monograph.* Danbury, CT: Mannkind Corporation; 2021.
120. Eli Lilly and Company: **Humulin 70/30**. In: *US Product Monograph.* Indianapolis, IN: Eli Lilly and Company; 2020.
121. American Diabetes Association: **9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021**. *Diabetes Care*2021, **44**(Suppl 1):S111-s124.
122. Novo\_Nordisk\_Canada\_Inc.: **NovoMix\_30\_(insulin\_aspart\_aspart\_protamine)**. In: *CA Product Monograph.* Mississauga, Ontario Novo\_Nordisk\_Canada\_Inc.; 2021.
123. Novo Nordisk Pharma Inc: **Insulin Aspart Protamine and Insulin Aspart Mix 70/30**. In: *US Product Monograph.* Plainsboro, NJ: Novo Nordisk Pharma Inc; 2020.
124. ELI\_LILLY\_Canada: **Humalog\_(Insulin\_lispro Insulin Lispro Protamine)\_CA**. In: *CDN Product Monograph.* Toronto, ON: ELI\_LILLY\_Canada; 2021.
125. Company ELa: **Humalog Mix 50/50 (Insulin lispro insulin lispro protamine)**. In: *FDA Product Monograph.* Indianapolis, IN: Eli Lilly and Company; 2021.